Drug Profile
ARC 165395XX
Alternative Names: AR-C165395XXLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Tablet)
- 01 May 2015 AstraZeneca completes a phase I trial in Type-2 diabetes mellitus in USA (NCT02367066)
- 01 Mar 2015 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)